Conference Reports for NATAP

ID Week Oct 8-12 2014 Philadelphia Back

HCV at IDSA - Bone Disease Greater in HIV+ HCV or HBV Coinfected / Barriers to Care / Hi Prevalence 7% at STD Clinic in Baltimore / 20% of HIV+ Never Tested for HCV / New HCV Therapies: Ledipasvir/Sofosbuvir & Abbvie 3D Data Summaries       Jules Levin, NATAP   Plenary Overview- HCV Treatment Cascade: Is Eradication Possible? - (10/10/14)   Plenary Overview - HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management - (10/15/14)   Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)   Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)   Hepatitis C Care among HIV Infected Patients in a Community Based Clinic (Ryan White Clinic/Baltimore) - (10/15/14)   Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to care - Hi prevalence 7%, low attendance at offsite HCV specialist appointments - (10/15/14)   Prevalence of and Factors Associated with Hepatitis C Virus Testing and Infection Among HIV-infected Adults Receiving Medical Care in the United States .... 20% Never Tested/21% HCV+/MSM Lo % Tested/Homelessness associated with HCV+ - (10/15/14)   Optimization of the HCV Testing and Care Continuum in an Urban Federally Qualified Health Center in Denver - (10/15/14)   (non-Genotype 1) - Non-Type 1 HCV Predicts Sustained Virologic Response in Cancer Survivors - written by Mark Mascolini - (10/14/14)   ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES - (10/15/14)   Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (10/15/14)